Additionally, the TIDE scores were markedly elevated in the OLR1 high-expression subgroup in contrast to the OLR1 low-expression subgroup, implying that HNSCC patients with higher OLR1 expression levels were more likely to be resistant to ICI therapy than those with lower OLR1 expression levels (p < 0.001, Figure 6J). The gene discussed is OLR1; the disease is head and neck squamous cell carcinoma.